DNB//Back Bay publishes industry reports on the healthcare sector. Reports are authored by Back Bay Life Science Advisors’ experts on global life science development and DNB’s senior equity analysts.
The latest in our series of healthcare analyst reports is now available and focuses on the rapid growth of bispecific or multi-specific antibodies (msAbs). With now 14 FDA-approved msAbs and nearly 250 assets in clinical development, msAbs are indeed entering an age of innovation and commercial validation.
Read MoreThe second in our series of healthcare development reports focuses on the clinical and market needs within the GLP-1 space and how biopharma, investors and academia view the next obesity breakthrough.
Read MoreFRONTIERS IN CNS THERAPEUTIC DEVELOPMENT
Disorders of the central nervous system (CNS) have steadily increased over the past 30 years, with neurological disease now constituting the world’s leading cause of disability and health burden.
Despite the number of organizations developing potentially transformative therapies to address these diseases, most drugs designed to treat neurological illness struggle to cross the brain’s protective barrier – known as the blood-brain barrier (BBB).
Various approaches are being explored to overcome this pharmacological challenge. The DNB//Back Bay Partnership analyzed the clinical development landscape, recent transactions, and financing activity to better understand which technologies are advancing to the clinic and gaining traction.
Read More
